Skip to main content
25 February 2021
Last updated:
Wednesday 24 February 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
    • Research Directory
    • Organisations
    • Interviewees
    • Terms
    • Topics
  • Contact Us

Research Directory

  • JAK2 inhibitors: a breakthrough in oncology?

    Thursday 23 September 2010
    Interviewee/Contributor
    Jürg Eckhardt
    Organisation
    Bellevue Asset Management
    Cancer (Oncology)
    Janus kinase 2 inhibitors - JAK2 inhibitors
    • Read more about JAK2 inhibitors: a breakthrough in oncology?

Organisations

  • CellCentric Ltd
  • ICON Commercialisation and Outcomes
  • Oslo Cancer Cluster, Radforsk
  • Allergy Therapeutics Plc
  • Ares Genetics GmbH
  • University of Pennsylvania, Perelman School of Medicine
  • University of Medicine and Dentistry of New Jersey
  • Celtic Pharma Holdings
  • Enterome SA
  • Wellcome Trust

Interviewees and Contributers

  • Ingmar Hoerr
  • Dr Tim Andrews
  • Ruth McKernan
  • Neil Miller
  • Edwin Moses
  • John Purves
  • Jean-Philippe Tripet
  • Donald Light
  • Jennifer Hannesschlager
  • Keith Flaherty

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Microbiotica expands management team
Wednesday February 10 2021
Philippe Dro joins Scenic Biotech as independent chairman
Wednesday February 10 2021
NOXXON announces senior appointment to its new advisory board
Wednesday February 10 2021
Wendy Levin joins Biofidelity as chief medical officer
Wednesday February 10 2021
VarmX appoints Gerard Short as chief medical officer
Wednesday February 10 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.